Sodium-channel blocker challenge in the familial screening of Brugada syndrome: safety and predictors of positivity


To cite this version:
Dylan Therasse, Frédéric Sacher, Bertrand Petit, Dominique Babuty, Philippe Mabo, et al.. Sodium-channel blocker challenge in the familial screening of Brugada syndrome: safety and predictors of positivity. Heart Rhythm, 2017, 14 (10), pp.1442-1448. 10.1016/j.hrthm.2017.06.031 . hal-01650124

HAL Id: hal-01650124
https://univ-rennes.hal.science/hal-01650124
Submitted on 28 Nov 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Sodium-channel blocker challenge in the familial screening of Brugada syndrome:
safety and predictors of positivity.

Dylan THERASSE¹, MD, Frederic SACHER², MD, Bertrand PETIT³, MD, Dominique
BABUTY⁴, MD, PhD, Philippe MABO⁵, MD, PhD, Raphael MARTINS⁵, MD, PhD,
Laurence JESEL⁶, MD, Philippe MAURY⁷, MD, PhD, Jean Luc PASQUIE⁸, MD, PhD,
Jacques MANSOURATI⁹, MD, PhD, Jean Marc DUPUIS¹⁰, MD, Florence KYNDT¹¹, ¹²,
PharmaD, PhD, Aurélie THOLLET¹, PharmaD, PhD, Beatrice GUYOMARCH¹, Julien
BARC¹², PhD, Jean Jacques SCHOTT¹, PhD, Herve LE MAREC¹, MD, PhD, Richard
REDON¹, PhD, Vincent PROBST¹, MD, PhD, Jean-Baptiste GOURRAUD¹, MD, PhD.
¹ l’institut du thorax, INSERM, CNRS, UNIV Nantes, CHU Nantes, Nantes, France; ² CHU
Bordeaux, Hôpital cardiologique, Bordeaux, France; ³ CHR La Réunion, Service de
Cardiologie, Saint Pierre, France; ⁴ CHU Tours, Service de cardiologie, Tours, France; ⁵ CHU
Rennes, Service de cardiologie, Rennes, France; ⁶ CHU Strasbourg, Service de cardiologie,
Strasbourg, France; ⁷ CHU Toulouse, Service de cardiologie, Toulouse, France; ⁸ CHU
Montpellier, Service de cardiologie, Montpellier, France; ⁹ CHU Brest, Service de
cardiologie, Brest, France; ¹⁰ CHU Angers, Service de cardiologie, Angers, France; ¹¹ CHU
Nantes, Service de Génétique Médicale, Nantes, F-44000 France; ¹² l’institut du thorax,
INSERM, CNRS, UNIV Nantes, Nantes, France.

Short title: Sodium channel blockers test in familial Brugada syndrome

Corresponding author: Jean-baptiste Gourraud, Service de cardiologie, CHU de Nantes,
Hôpital Nord Laennec, boulevard Jacques Monod, 44093 Nantes cedex, France; tel: +33-240-
165-009; fax: +33-240-165-024 ; e-mail: jeanbaptiste.gourraud@chu-nantes.fr

Conflicts of Interest statement: The authors have no conflicts of interest nor financial
relationships relevant to this article to disclose.

Word count: 4509
**ABSTRACT**

**Background:** Sodium channel blocker challenge (SCBC) is frequently performed to unmask Brugada syndrome (BrS).

**Objectives:** We aim to identify, predictors of positivity and complications of SCBC, in the setting of familial screening.

**Methods:** All consecutive patients from 2000 to 2014 who benefit from a SBC and belong to a family with at least 2 subjects affected by the syndrome were enrolled and followed prospectively. Data were reviewed by 2 physicians blinded to the clinical and genetic status.

**Results:** Among 672 SCBC performed in 137 families, 337(50%) were positive. Multivariate analysis identified ajmaline (OR 2.98 (1.65-4.91), a significant S wave in DII (OR=3.11 (2.12-4.58), DIII (OR= 2.75 (1.78-4.25) or V5 lead (OR= 3.71 (2.54-5.44), as predictors of a positive SCBC (P <0.0001). Eleven (1.6%) patients presented complications (10 ventricular arrhythmia, 1 atrial flutter) but no deaths occurred. A familial history of complications (OR = 41 [10; 203]; P<0.0001), young age (P =0.04) and decreased conduction ECG parameters at baseline (p=0.04) were predictors of complication. QRS enlargement during SCBC was not associated with complications.

During a median follow-up of 106 [54-143] months, 11 life-threatening arrhythmia occurred.

**Conclusions:** SCBC in the screening of familial Brs is safe. The risk of complication is considerably increased in case of familial history of complicated SCBC, in very young patients and in the presence of decreased ECG conduction parameters. However, QRS enlargement during the test is not directly related to complications and should not be used to prematurely stop the test unless leading to false negative results.

**Key words:** Brugada syndrome; Sodium Channel Blockers Challenge; Ajmaline; Flecaïnide; Complication.
Introduction

Brugada syndrome (BrS) is responsible for sudden cardiac death (SCD) due to ventricular fibrillation (VF) which typically occurs at rest and could be the first manifestation of the disease\(^1\). Diagnosis is based on a specific ECG pattern – type 1 ST segment elevation in the right precordial leads as defined in the recent guidelines\(^2\). Owing to the variability of this ECG pattern, its prevalence in the general population remains unclear but has been estimated to range between 0.05% and 0.2%\(^3-5\). In subjects without spontaneous type 1 ECG aspect, sodium channel blocker challenge (SCBC) is commonly used to unmask the ECG pattern\(^2,6\). Ajmaline and flecainide are the most commonly used drugs while Procainamide is considered as less efficient\(^6\).

While this test is widely used, its safety remains a matter to debate \(^7-11\). Indeed, last guidelines consider as a stopping criteria, a QRS enlargement of more than 30%\(^2\). Challenging this criteria, Batchvarov et al have suggested that it can lead to underdiagnose BrS while the risk of complications in this situation appears to be low\(^7\).

The aim of this study was to evaluate, aside from QRS enlargement stopping criteria, the safety and predictors of a positive SCBC, during familial screening of Brs.
Methods

Study Population and design

All consecutive patients undergoing SCBC during familial screening of Brs, in 10 French university hospitals from 2000 to 2014, were included. This study was conducted according to European guidelines for clinical and genetic research. Informed written consent was obtained from each patient who agreed to participate in the clinical and genetic study.

Except for QRS enlargement stopping criteria, SCBCs were performed according to the second consensus conference (Ajmaline: 1 mg/kg; Flecainide: 2 mg/kg). Complications were defined as occurrence of ventricular arrhythmias (VF) and sustained or non-sustained ventricular tachycardia (VT), atrial arrhythmias or atrioventricular block.

The diagnosis of BrS was based on 2013 criteria with the presence of a typical type 1 ECG pattern, either spontaneous or pharmacologically induced, in at least one right precordial lead including (V1, V2, V3) in the 2nd, 3rd or 4th intercostal space. Type 1 ST segment elevation was defined as a J-wave elevation higher than 0.2mV, followed by a coved type ST segment elevation and ended with a negative T wave.

Clinical follow-up was collected prospectively from either the referring cardiologists or directly from the patients.

ECG data

Two physicians blinded to the clinical and genetic status reviewed baseline ECG, first diagnosis ECG during SCBC or ECG at the end of the test in case of negative test.

P wave, PQ interval, QRS, QT peak, QTend, QTc duration (corrected by Bazett’s formula) and Tpeak-Tend interval (TPE, time interval between the peak and the end of the T wave) were measured in V1. Additional parameters were measured in DII (terminal S wave
duration and amplitude), DIII (terminal S wave duration and amplitude), V5 (terminal S wave duration and amplitude) and aVR (terminal R wave duration and amplitude).

All measurements were performed using Image J software (National Institutes of Health, Bethesda, Maryland, http://rsb.info.nih.gov/ij).

Genetic analysis

The SCN5A gene was screened in each proband. Relatives were screened for familial mutations according to the genetic status of the proband.

Genomic DNA was extracted from peripheral blood leukocytes using standard protocols. All 28 exons of SCN5A were amplified by polymerase chain reaction (PCR) utilizing intronic primers. PCR products were screened for SCN5A mutations using denaturing high performance liquid chromatography (dHPLC)-DNA sequencing or High Resolution Melting (HRM). The description of mutations is based on cDNA reference sequence GenBank NM_198056.

This study was conducted according to European guidelines for clinical and genetic research. Institutional ethical committees approved clinical and genetic database. Informed written consent was obtained from each patient who agreed to participate in the clinical and genetic study.

Statistical Analysis

Data were analysed with the SPSS and SAS packages (SPSS Inc version 23.0, Chicago, Ill; SAS Institute Inc version 9.4, Cary, NC).

Continuous variables were reported as mean ± SD or median (lower quartile, upper quartile), as appropriate. Continuous variables were analysed by Student’s unpaired t-test or the Wilcoxon test, as appropriate. The χ² test and Fisher’s exact test were used for comparison of categorical variables.

Multivariate logistic regression models were used to identify provider-related factors associated with positive tests.
All tests were 2 tailed and a $P$ value under 0.05 was considered as statistically significant.
Results

Population

The study population consist of 672 consecutive patients from 137 families (median age 40 ± 17 years). Three hundred and twenty-eight patients were male (49%). Three hundred and thirty-seven patients (50%) presented a positive SCBC with an induced type 1 ECG pattern. The molecule used was ajmaline in 497 (74%) and flecainide in 175 (26%) SCBC. SCN5A mutation was identified in 43/136 (31%) probands and in 120/268 (45%) of their relatives. Population characteristics are summarized in Table 1.

Characteristics of positive SCBC

Among the 672 SCBC, a positive result was associated with age (41+/− 16 vs 36 +/- 17 y; p=0.004), the presence of a SCN5A mutation in the family (93 (79%) vs 27 (28%); p<0.001) and the use of ajmaline (272 (54%) of positive SCBC vs 65 (37%) for flecainide; p<0.001) (figure 1).

Patients with a positive SCBC additionally presented at baseline a longer P wave (68 ± 19 ms vs 62 ± 17 ms; P <0.001), PR (156 ± 31 ms vs 146 ± 27 ms; P <0.001) and QTc interval (407 ± 39 ms vs 394 ± 36 ms; P <0.001) in V1 lead and a longer QRS interval (92 ± 19 ms vs 82 ± 16 ms; P <0.001) in DII lead. Both duration and amplitude of the terminal S wave in DII, DIII and V5 leads and the terminal R wave in aVR were also associated with a positive SCBC (P <0.0001). Similar results were observed at the end of the SCBC (Table 2).

In multivariate analysis, the drug used (ajmaline vs flecainide) was the best predictor of a positive SCBC (OR 2.98 (1.65-4.91); P <0.0001). A significant S wave (e.g., amplitude > 1 mV and duration > 40 ms) in DII (OR=3.11 (2.12-4.58), P <0.0001, DIII (OR= 2.75 (1.78-4.25), P <0.0001) and V5 lead (OR= 3.71 (2.54-5.44), P <0.0001) or a significant terminal R wave in aVR (OR= 2.22 (1.51-3.26), P <0.0001) were also associated with a positive SCBC (Figure 1).
Complications

Among the 672 SCBC performed, complications occurred in 11 (1.6%) including 9 sustained VT, one VF and one atrial flutter. Four of these patients required external DC shock. There were neither high-grade conduction disorders, nor deaths caused by SCBC.

Three families presented complications during SCBC in several (2 to 3) family members. SCN5A variant segregating with the phenotype has been identified in those three families. The (c.2254G>A) has been previously described as a mutation. The two others (c.2998C>T and c.5417_5420del) are frameshift or non-sense variant whose one has been previously described.

The main clinical risk factor for complications was familial history of complicated SCBC (OR = 41 [10; 203]; P <0.0001) and younger age (median age 21 ± 18 v 42 ±16 years; P =0.04). There was a non-significant trend to a higher risk of complications with the use of ajmaline (11 complications /497 SCBCs for ajmaline vs 0/175 for flecainide; P =0.07).

Complications were also associated with a longer P wave (114 ± 16 vs 92 ± 18 ms; P =0.004) and PR interval (192 ± 27 ms vs 162 ± 28 ms; P =0.004) at baseline. The terminal S wave in lead DII (65 ± 25 ms vs 32 ± 23 ms; P <0.0001), DIII (57 ± 30 ms vs 25 ± 27 ms; P <0.0001) and the terminal R wave in aVR (50 ± 16 ms vs 30 ± 21 ms; P <0.0001) duration were also significantly larger in complicated SCBC.

QRS duration during SCBC was not associated with complications (133 ± 21 ms vs 134 ± 35 ms; P =0.9) (figure 2). However, among the 11 patients with complications, 6 (54%) does not achieve the drug challenge leading to decrease the median dose of sodium channel blocker to 0.25 (0.2-0.5) mg/kg. Additionally, median QRS enlargement during the test trend to be higher in the presence of complication (133%+- 22 vs 127% +- 31; p=0.06).

Fifty-seven percent of patient with positive tests and 39% of patients with negative tests had a QRS enlargement higher than 30% in DII lead.
Clinical Follow-up

After a median follow-up of 106 [54-143] months, 11 patients (73% male; mean age: 38 ± 18 y) experienced life-threatening arrhythmia including 1 SCD, 1 aborted SCD and 9 appropriate shocks. These nine patients who experienced apppropriated shock had positive SCBC.
**Discussion**

SCBC is the cornerstone of Brs screening as it allows unmasking the diagnostic Brugada ECG pattern particularly during familial screening. Considering the doubt about SCBC safety and a low risk of arrhythmia in asymptomatic relatives with undiagnosed baseline ECG, some argue this familial screening should be restricted\(^\text{15}\). However, diagnosis in such patients can allow to introduce general lifestyle changes preventing arrhythmia occurrence and to carry on with the familial screening in descendant, which can present a higher risk of arrhythmia\(^\text{16}\).

Overall, our study demonstrated that SCBC is safe. The complication rate was only 1.6%, confirming the safety of this test when performed in an appropriate environment\(^\text{8}\). We identified that family history of adverse events during the SCBC represents the stronger risk factor for the occurrence of arrhythmia during the test. Indeed, 63% of the complications (7/11) in our study involved 3 out of the 137 families studied. This data suggests that these families have an increased susceptibility to the occurrence of complications probably due to a particular genotype. Of note, a SCN5A mutation was found in these three families. Those families presented with segregation of a SCN5A variant, whose one has been previously described as a mutation\(^\text{12,13}\) and the two others are frameshift or nonsense mutation that may lead to a decreased Na current and an increased effect of sodium channel blockers\(^\text{14}\).

However, the phenotype we observed has never been described in previous studies of patients carrying the same mutation.

Patients with complications were also younger (median age: 21 ± 18 years). As recently described by Conte\(^\text{17}\), the risk of complications is increased in children. In our study, 8 patients were under 16 years of age at the time of the SCBC and 3 (37.5%) presented a complication during the test that is from far higher than in the rest of the population. There is currently no clear explanation for this increased rate. In children, because of the absence of
fibrosis of the his bundle and its branches, there is a good security factor allowing a normal or
subnormal propagation of the cardiac influx even in case of decrease of the sodium current,
such with SCN5A mutation\cite{18}. This may explain the rarity of the Brugada syndrome in
children\cite{19,20}. However, although Brs is relatively rare in children, it appears to be associated
with an increased rate of conduction disturbance at baseline\cite{17,19–21}. Then, SCN5A mutation
are from far more frequent in children with Brs than in adult\cite{20} that confirm the importance of
a decreased sodium current to unmask the Brugada syndrome in children. This suggests that
the presence of conduction abnormalities (even minor) in children is in fact in relation with a
strong decrease of the ability of the cardiac influx to propagate into the conduction tissue. In
this situation, the addition of a sodium cardiac blocker could lead to a dramatic decrease of
the conduction and then to severe complications. This is in line with the fact that, in our study,
conduction disturbance at baseline is associated with complication occurrence. Notably, the
presence of a terminal S wave in DII, DIII and V5 or a terminal R wave in aVR, which can
represent enhanced conduction delay in the right ventricular outflow tract (RVOT)\cite{22}, depict
patients at higher risk of complications during the test.

QRS enlargement during the test was previously related to a high risk of
complications\cite{6}. As previously suggested by Batchvarov\cite{7}, our study demonstrates that a
significant number of patients have an enlargement of the QRS over 30% before the end of
the test. In fact, 57% of patient with positive tests had a QRS enlargement higher than 30%
meaning that if we had strictly followed the guidelines, the sensitivity of the test will have
been dramatically decreased while the risk of complications in this situation appears to be
low. Then, our results suggest changing the guidelines, as stopping prematurely the test for
QRS enlargement of more than 30% will lead to an unacceptable number of patients
undiagnosed without significantly decreasing the risk of complications. However, as
demonstrated in several case reports\cite{9,23,24}, management of such QRS enlargement could
require specific attention. Indeed, in the complicated group, the QRS enlargement appears to be faster despite a lower dosage of SCN5A channel blockers. Although we are not able to identify stopping criteria according to the QRS enlargement kinetic, a fast enlargement during the test may sensitize the physician about the risk of complication. As a consequence, SCBC should always be performed in experienced center.

**ECG criteria to detect patients at high risk of a positive test**

We demonstrated that significant S wave in inferolateral leads and terminal R wave in aVR lead at baseline were associated with a positive response to SCBC. These results confirm previous study\(^2^5\) and can help to select patients who need the test to confirm the diagnosis of BrS. It also provides interesting findings in BrS pathogenesis. The third vector of cardiac depolarization, generating both such wave exhibits the depolarization of basal myocardium and in particular, the right ventricular outflow tract (RVOT)\(^2^2,2^6\). Baseline conduction disturbances, especially axial deviation with prominent S wave in inferior or lateral leads, highlight the role of conduction delay in the RVOT\(^2^7,2^8\). This was recently emphasized by Calò who suggests the prognostic value of RVOT conduction delay using S wave in DI lead\(^2^2\). Our results reinforce the importance of conduction disturbance in the RVOT that appear to be essential both in the diagnosis and prognosis of BS patients.

**Study limitations:**

This study was a retrospective and multicentric study. Then, SCBC procedures are different with particular differences in the administration of drugs (continuous intravenous or bolus injection). However, identical diagnostic performances have been demonstrated on suspected Brugada electrocardiograms\(^2^9\).
Conclusion

We demonstrated that SCBC appears to be safe. The risk of complication is considerably increased in patients with a familial history of complicated SCBC and in very young patients. Specific ECG markers should also be used to detect patients at higher risk. Notably, a fast enlargement during the test may sensitize the physician about the risk of complication.

Although conduction disturbance appears efficient to predict a positive test, QRS enlargement is not significantly related to complications in our study. It should not be used to prematurely stop the test unless leading to false negative results. However,
Acknowledgements: We would like to first thank families who agreed to be involved in this study. We are also grateful to the “Centre de référence des maladies rythmiques héréditaires” and to the molecular diagnosis team of the university hospital of Nantes, for their help in this study.

Funding source: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest statement: The authors have no conflicts of interest nor financial relationships relevant to this article to disclose.
References


Tables

Table 1: description of the population

SCBC: sodium channel blocker challenge

SCD: sudden cardiac death

<table>
<thead>
<tr>
<th></th>
<th>Groups</th>
<th>Total</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Positive SCBC</td>
<td>Negative SCBC</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>337 (50%)</td>
<td>335 (50%)</td>
<td>672</td>
</tr>
<tr>
<td>Age (years)</td>
<td>41 +/- 16</td>
<td>36 +/- 17</td>
<td>40 +/- 17</td>
</tr>
<tr>
<td>Sex: male (n (%))</td>
<td>154 (46%)</td>
<td>174 (52%)</td>
<td>328 (49%)</td>
</tr>
<tr>
<td>Syncope (n (%))</td>
<td>82 (9%)</td>
<td>18 (2%)</td>
<td>11 (1.6%)</td>
</tr>
<tr>
<td>Familial history of SCD (n (%))</td>
<td>142 (42%)</td>
<td>123 (37%)</td>
<td>265 (39%)</td>
</tr>
<tr>
<td>number of affected relatives (median)</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>SCN5A mutation in family (n, %)</td>
<td>93 (79%)</td>
<td>27 (28%)</td>
<td>120 (45%)</td>
</tr>
<tr>
<td>Molecule used</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ajmaline</td>
<td>272 (81%)</td>
<td>225 (67%)</td>
<td>497 (74%)</td>
</tr>
<tr>
<td>Flecaainide</td>
<td>65 (19%)</td>
<td>110 (33%)</td>
<td>175 (26%)</td>
</tr>
</tbody>
</table>
Table 2: ECG parameters according to sodium channel blocker challenge results

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>End of the test</th>
<th>p value</th>
<th>Baseline</th>
<th>End of the test</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SCBC + (n=326)</td>
<td>SCBC - (n=328)</td>
<td>p value</td>
<td>SCBC + (n=328)</td>
<td>SCBC - (n=329)</td>
<td>p value</td>
</tr>
<tr>
<td><strong>DII (ms)</strong></td>
<td></td>
<td></td>
<td></td>
<td>SCBC + (n=328)</td>
<td>SCBC - (n=329)</td>
<td>p value</td>
</tr>
<tr>
<td>QRS</td>
<td>92 ± 19</td>
<td>82 ± 16</td>
<td>&lt; 0.0001</td>
<td>123 ± 24</td>
<td>101 ± 20</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td><strong>V1 (ms)</strong></td>
<td></td>
<td></td>
<td></td>
<td>SCBC + (n=328)</td>
<td>SCBC - (n=329)</td>
<td>p value</td>
</tr>
<tr>
<td>P</td>
<td>68 ± 19</td>
<td>62 ± 17</td>
<td>&lt; 0.0001</td>
<td>83 ± 22</td>
<td>72 ± 19</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>PQ</td>
<td>156 ± 31</td>
<td>146 ± 27</td>
<td>&lt; 0.0001</td>
<td>201 ± 40</td>
<td>178 ± 35</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>QRS</td>
<td>94 ± 17</td>
<td>91 ± 15</td>
<td>0.06</td>
<td>112 ± 26</td>
<td>103 ± 20</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>QT peak</td>
<td>299 ± 34</td>
<td>299 ± 34</td>
<td>0.99</td>
<td>317 ± 37</td>
<td>298 ± 36</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>QTc</td>
<td>407 ± 39</td>
<td>394 ± 36</td>
<td>&lt; 0.0001</td>
<td>468 ± 51</td>
<td>420 ± 38</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>TPE</td>
<td>71 ± 25</td>
<td>68 ± 17</td>
<td>0.0005</td>
<td>90 ± 27</td>
<td>75 ± 22</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td><strong>S duration (ms)</strong></td>
<td></td>
<td></td>
<td></td>
<td>SCBC + (n=328)</td>
<td>SCBC - (n=329)</td>
<td>p value</td>
</tr>
<tr>
<td>DII</td>
<td>35 ± 24</td>
<td>23 ± 21</td>
<td>&lt; 0.0001</td>
<td>58 ± 27</td>
<td>35 ± 24</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>DIII</td>
<td>33 ± 28</td>
<td>20 ± 24</td>
<td>&lt; 0.0001</td>
<td>47 ± 36</td>
<td>28 ± 28</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>V5</td>
<td>42 ± 19</td>
<td>28 ± 18</td>
<td>&lt; 0.0001</td>
<td>67 ± 21</td>
<td>50 ± 16</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td><strong>R duration (ms)</strong></td>
<td></td>
<td></td>
<td></td>
<td>SCBC + (n=328)</td>
<td>SCBC - (n=329)</td>
<td>p value</td>
</tr>
<tr>
<td>aVR</td>
<td>32 ± 22</td>
<td>25 ± 20</td>
<td>&lt; 0.0001</td>
<td>52 ± 25</td>
<td>35 ± 22</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td><strong>S amplitude (mV)</strong></td>
<td></td>
<td></td>
<td></td>
<td>SCBC + (n=328)</td>
<td>SCBC - (n=329)</td>
<td>p value</td>
</tr>
<tr>
<td>DII</td>
<td>1.72 ± 1.7</td>
<td>1.2 ± 1.5</td>
<td>&lt; 0.0001</td>
<td>3 ± 2.2</td>
<td>2.2 ± 2.8</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>DIII</td>
<td>2 ± 2.8</td>
<td>1.3 ± 2.5</td>
<td>&lt; 0.0001</td>
<td>2.5 ± 2.9</td>
<td>1.8 ± 2.6</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>V5</td>
<td>3.5 ± 3</td>
<td>2.6 ± 2.9</td>
<td>&lt; 0.0001</td>
<td>7 ± 4.8</td>
<td>5 ± 3.5</td>
<td>0.0003</td>
</tr>
<tr>
<td><strong>R amplitude (mV)</strong></td>
<td></td>
<td></td>
<td></td>
<td>SCBC + (n=328)</td>
<td>SCBC - (n=329)</td>
<td>p value</td>
</tr>
<tr>
<td>aVR</td>
<td>1.5 ± 2.1</td>
<td>1.1 ± 1.78</td>
<td>&lt; 0.0001</td>
<td>2.4 ± 1.5</td>
<td>1.9 ± 2.6</td>
<td>&lt; 0.0001</td>
</tr>
</tbody>
</table>
Figures legend

Figure 1: Example of a positive SCBC.

The test (ajmaline 1mg/kg over 10 min) was performed in an asymptomatic 18 yo woman after the identification of a symptomatic BrS in her father.

Please note the S wave in DII and DIII on baseline ECG and the QRS fragmentation in precordial leads.

Measurement performed in 3 consecutive beats reveal a significant increased in the PR interval (from 268 ms to 304 ms), the QRS interval (from 81 ms to 143 ms) and the QT interval (from 381 ms to 420 ms) during the test. All ECG was performed with a 25 mm/s speed and a 10 mm/mV amplitude. No complication occurred during the test.

Figure 2: Proportion of positive and complicated SCBC according to QRS enlargement

Percentage of positive SCBC according to QRS enlargement is represented in blue.

Percentage of complicated SCBC according to QRS enlargement is represented in red.